Tetanus Drugs In Development, 2021 Pipeline Landscape Report - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Tetanus (Infectious Disease) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.
Tetanus - Drugs In Development, 2021, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.
Tetanus - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 5, 11, 1, 13, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.
Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Tetanus - Overview
- Tetanus - Therapeutics Development
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Tetanus - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Tetanus - Companies Involved in Therapeutics Development
- AIM Vaccine Co Ltd
- Beijing Minhai Biotechnology Co Ltd
- Beijing Tiantan Biological Products Co Ltd
- Biken Co Ltd
- Biological E Ltd
- BioNet-Asia Co Ltd
- Boryung Pharmaceutical Co Ltd
- Cadila Healthcare Ltd
- CanSino Biologics Inc
- Changchun Bcht Biotechnology Co Ltd
- Chengdu Kanghua Biological Products Co Ltd
- Chongqing Zhifei Biological Products Co Ltd
- GC Pharma
- GlaxoSmithKline Plc
- KM Biologics Co Ltd
- LG Chem Ltd
- Novo Medi Sciences Pvt Ltd
- NTxBio LLC
- Olymvax Biopharmaceuticals Inc
- Panacea Biotec Ltd
- Seasons Healthcare Ltd
- Serum Institute of India Pvt Ltd
- Shantha Biotechnics Pvt Ltd
- Sichuan ZehaTimes Pharmaceutical Co Ltd
- Stablepharma Ltd
- VaxForm LLC
- Yisheng Biopharma Co Ltd
- Yuxi Jiuzhou Biological Technology Co Ltd
- Zhuhai Trinomab Biotechnology Co Ltd
Tetanus - Drug Profiles
- Adacel plus
- Antibody for Tetanus
- DTcP vaccine
Tetanus - Dormant Projects
Tetanus - Discontinued Products
Tetanus - Product Development Milestones
Featured News & Press Releases
- Mar 11, 2019: LG Chem gets $33.4 mil. from Gates Foundation for vaccine development
- Aug 02, 2016: CanSino submits a clinical trial application for the component DTP diptheria tetanus pertussis combo vaccine (adults, teenagers and children above 6 years Old)
- Sep 01, 2015: Commercialisation of a world changing invention for the stabilisation and delivery of vaccines
- Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
For more information about this report visit https://www.researchandmarkets.com/r/60de5j
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900